References
- Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary artery disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893–8.
- Steiner G. Diabetes and atherosclerosis—a lipoprotein perspective. Diabetic Med 1997; 14: S38–S44.
- Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary artery disease in young type I (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1985; 28: 590–6.
- Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.
- DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977–86.
- United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
- Turner RC, Millns H, Neil HAW et al., for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus (UKPDS 23). Br Med J 1998; 316: 823–8.
- American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; Suppl 1: S68–71.
- Haffner SM. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: Implications for the prevention of coronary heart disease. Diabetes Care 1997; 20: 469–71.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trail. Lancet 2003: 361: 2005–16.
- Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96.
- The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 patients with type 2 diabetes (the FIELD Study) randomised controlled trial. Lancet 2005; 366: 1849–61.
- Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93.